Supitcha Kamolratanakul

Dr. Supitcha Kamolratanakul

Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University,
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
Supitcha KamolratanakulSupitcha Kamolratanakul
Supitcha Kamolratanakul
Punnee PitisuttithumPunnee Pitisuttithum
Punnee Pitisuttithum
Human papillomavirus (HPV) is the most common sexually transmitted infection, with 15 HPV types related to cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers. However, cervical cancer remains one of the most common cancers in women, especially in developing countries. Three HPV vaccines have been licensed: bivalent (Cervarix, GSK, Rixensart, Belgium), quadrivalent (Merck, Sharp & Dome (Merck & Co, Whitehouse Station, NJ, USA)), and nonavalent (Merck, Sharp & Dome (Merck & Co, Whitehouse Station, NJ, USA)). The current HPV vaccine recommendations apply to 9 years old and above through the age of 26 years and adults aged 27–45 years who might be at risk of new HPV infection and benefit from vaccination. The primary target population for HPV vaccination recommended by the WHO is girls aged 9–14 years, prior to their becoming sexually active, to undergo a two-dose schedule and girls ≥ 15 years of age, to undergo a three-dose schedule. Safety data for HPV vaccines have indicated that they are safe. The most common adverse side-effect was local symptoms. HPV vaccines are highly immunogenic. The efficacy and effectiveness of vaccines has been remarkably high among young women who were HPV seronegative before vaccination. Vaccine efficacy was lower among women regardless of HPV DNA when vaccinated and among adult women. Comparisons of the efficacy of bivalent, quadrivalent, and nonavalent vaccines against HPV 16/18 showed that they are similar. However, the nonavalent vaccine can provide additional protection against HPV 31/33/45/52/58. In a real-world setting, the notable decrease of HPV 6/11/16/18 among vaccinated women compared with unvaccinated women shows the vaccine to be highly effective. Moreover, the direct effect of the nonavalent vaccine with the cross-protection of bivalent and quadrivalent vaccines results in the reduction of HPV 6/11/16/18/31/33/45/52/58. HPV vaccination has been shown to provide herd protection as well. Two-dose HPV vaccine schedules showed no difference in seroconversion from three-dose schedules. However, the use of a single-dose HPV vaccination schedule remains controversial. For males, the quadrivalent HPV vaccine possibly reduces the incidence of external genital lesions and persistent infection with HPV 6/11/16/18. Evidence regarding the efficacy and risk of HPV vaccination and HIV infection remains limited. HPV vaccination has been shown to be highly effective against oral HPV type 16/18 infection, with a significant percentage of participants developing IgG antibodies in the oral fluid post vaccination. However, the vaccines’ effectiveness in reducing the incidence of and mortality rates from HPV-related head and neck cancers should be observed in the long term. In anal infections and anal intraepithelial neoplasia, the vaccines demonstrate high efficacy. While HPV vaccines are very effective, screening for related cancers, as per guidelines, is still recommended.

19 February 2024 in Cells
Verified
Journal Article
Open access
PDF file
Supitcha KamolratanakulSupitcha Kamolratanakul
Supitcha Kamolratanakul
WAWassawon Ariyanon
Wassawon Ariyanon
KUKanyarat Udompornpitak
Kanyarat Udompornpitak
TBThansita Bhunyakarnjanarat
Thansita Bhunyakarnjanarat
Asada LeelahavanichkulAsada Leelahavanichkul
Asada Leelahavanichkul
WCWiwat Chancharoenthana
Wiwat Chancharoenthana
It is unclear how the immune system controls the transition from latent tuberculosis (TB) infection (LTBI) to active pulmonary infection (PTB). Here, we applied mass spectrometry cytometry time-of-flight (CyTOF) analysis of peripheral blood mononuclear cells to compare the immunological landscapes in patients with high tuberculous bacillary load PTB infections and LTBI. A total of 32 subjects (PTB [n = 12], LTBI [n = 17], healthy volunteers [n = 3]) were included. Participants with active PTBs were phlebotomized before administering antituberculosis treatment, whereas participants with LTBI progressed to PTB at the time of household screening. In the present study, CyTOF analysis identified significantly higher percentages of mucosal-associated invariant natural killer T (MAIT NKT) cells in subjects with LTBI than in those with active PTB and healthy controls. Moreover, 6 of 17 (35%) subjects with LTBI progressed to active PTB (LTBI progression) and had higher proportions of MAIT NKT cells and early NKT cells than those without progression (LTBI non-progression). Subjects with LTBI progression also showed a tendency toward low B cell levels relative to other subject groups. In conclusion, MAIT NKT cells were substantially more prevalent in subjects with LTBI, particularly those with progression to active PTB.

1 September 2022 in Burns
Verified
Journal Article
Closed access
JMJiraroch Meevassana
Jiraroch Meevassana
SSSiwat Serirodom
Siwat Serirodom
PPPiyawan Prabsattru
Piyawan Prabsattru
PBPapatson Boonsongserm
Papatson Boonsongserm
Supitcha KamolratanakulSupitcha Kamolratanakul
Supitcha Kamolratanakul
AAApichai Angspatt
Apichai Angspatt

15 June 2023 in Vaccine
Verified
Journal Article
Open access
SMSant Muangnoicharoen
Sant Muangnoicharoen
RWRakpong Wiangcharoen
Rakpong Wiangcharoen
SNSira Nanthapisal
Sira Nanthapisal
Supitcha KamolratanakulSupitcha Kamolratanakul
Supitcha Kamolratanakul
SLSaranath Lawpoolsri
Saranath Lawpoolsri
Punnee PitisuttithumPunnee Pitisuttithum
Punnee Pitisuttithum
The inactivated COVID-19 whole-virus vaccine BBIBP-CorV has been extensively used worldwide. Heterologous boosting after primary vaccination can induce higher immune responses against SARS-CoV-2 than homologous boosting. The safety and immunogenicity after 28 days of a single Ad26.COV2.S booster dose given at different intervals after 2 doses of BBIBP-CorV are presented. This open-label phase 1/2 trial was conducted in healthy adults in Thailand who had completed 2-dose primary vaccination with BBIBP-CorV. Participants received a single booster dose of Ad26.COV2.S (5×1010 virus particles) 90-240 days (Group A1; n=360) or 45-75 days (Group A2; n=66) after the second BBIBP-CorV dose. Safety and immunogenicity were assessed over 28 days. Binding IgG antibodies to the full-length pre-fusion Spike and anti-nucleocapsid proteins of SARS-CoV-2 were measured by enzyme-linked immunosorbent assay. The SARS-CoV-2 pseudovirus neutralization assay and live virus microneutralization assay were used to quantify the neutralizing activity of antibodies against ancestral SARS-CoV-2 (Wuhan-Hu-1) and the delta (B.1.617.2) and omicron (B.1.1.529/BA.1 and BA.2) variants. The cell-mediated immune response was measured using a quantitative interferon (IFN)-γ release assay in whole blood. Solicited local and systemic adverse events (AEs) on days 0-7 were mostly mild, as were unsolicited vaccine-related AEs during days 0-28, with no serious AEs. On day 28, anti-Spike binding antibodies increased from baseline by 487- and 146-fold in Groups A1 and A2, and neutralizing antibodies against ancestral SARS-CoV-2 by 55- and 37-fold, respectively. Humoral responses were strongest against ancestral SARS-CoV-2, followed by the delta, then the omicron BA.2 and BA.1 variants. T-cell–produced interferon-γ increased approximately 10-fold in both groups. A single heterologous Ad26.COV2.S booster dose after two BBIBP-CorV doses was well tolerated and induced robust humoral and cell-mediated immune responses measured at day 28 in both interval groups. Clinical Trials Registration. NCT05109559.

21 May 2023 in World Journal of Gastroenterology
Verified
Journal Article
Open access
WCWiwat Chancharoenthana
Wiwat Chancharoenthana
Supitcha KamolratanakulSupitcha Kamolratanakul
Supitcha Kamolratanakul
ALAsada Leelahavanichkul
Asada Leelahavanichkul
WAWassawon Ariyanon
Wassawon Ariyanon
SCSutatip Chinpraditsuk
Sutatip Chinpraditsuk
PWPolrat Wilairatana
Polrat Wilairatana
Gastrointestinal manifestations of long-term effects after COVID-19 infection in patients with dialysis or kidney transplantation: An observational cohort study

31 October 2020 in Asian Biomedicine
Verified
Journal Article
Open access
Supitcha KamolratanakulSupitcha Kamolratanakul
Supitcha Kamolratanakul
PTPravinwan Thungthong
Pravinwan Thungthong
CNChajchawan Nakhakes
Chajchawan Nakhakes
CKChokchai Kittiyanpanya
Chokchai Kittiyanpanya
PCPutza Chonsawat
Putza Chonsawat
SCSupat Chamnanchanunt
Supat Chamnanchanunt
Dengue virus infection most commonly has mild-to-moderate nonspecific clinical presentations that overlap with other diseases. Dengue-specific tests are commonly used for those patients with acute febrile illness in dengue-endemic areas. There is one study in vitro that showed a false-positive dengue-immunoglobulin M (dengue IgM) test for blood from a patient with systemic lupus erythematosus (SLE). Here, we demonstrated a false-positive dengue IgM test in a patient with SLE. The patient had fever, cytopenia, and a skin rash, but her clinical variables more closely matched with the criteria for SLE than the dengue infection. Vasculitis-like-lesions supported prednisolone administration and her clinical symptoms improved. This case highlights that some patients with SLE can be misdiagnosed as having a viral infection. These two diseases have similar clinical findings, such as acute febrile illness, but they are different in terms of their treatments and disease prognosis.